The Menarini Group and Radius Health, Inc. announced positive topline results from the EMERALD study evaluating elacestrant as a monotherapy versus the standard of care for the treatment of ER+/HER2- advanced or metastatic breast cancer.
[Menarini Group]
Sorry, but the selected Zotpress account can't be found.
